At 10.8% CAGR, the Asia Pacific Breast Cancer Therapeutics Market is Projected to be Worth US$ 15,819.83 Million by 2030, Says Business Market Insights

According to Business Market Insights research, the Asia Pacific breast cancer therapeutics market was valued at US$ 6,986.37 million in 2022 and is expected to reach US$ 15,819.83 million by 2030, registering a CAGR of 10.8% from 2022 to 2030. Increased support from government and private organizations is among the critical factors attributed to the Asia Pacific breast cancer therapeutics market expansion. 

Governments of various countries recognize the importance of addressing breast cancer and are implementing policies to improve access to effective treatments. Many governments and private organizations have increased funding for research and development in breast cancer therapeutics, resulting in the development of innovative drugs and therapies. In 2021, as part of the Swasth Mahila, Swasth Goa initiative, 100 thousand Goan women in India intended to receive free breast cancer screenings, indicating that 50% of the states age-eligible female population will receive screenings. The increased investment in research has allowed pharmaceutical companies to explore new treatment options and develop highly targeted and effective therapies for breast cancer patients.

Several government bodies across the world are also taking steps to improve access to these treatments by implementing reimbursement policies and healthcare initiatives that cover the cost of breast cancer therapeutics for patients. This means that more patients can afford these treatments and have access to the latest advancements in breast cancer therapeutics. The increased government support has also created a favorable market environment for healthcare providers. With more funding and resources available, healthcare providers are able to offer their patients a wider range of treatment options. This improves patient outcomes and allows healthcare providers to stay competitive in the market. Overall, the increased support from governments and private organizations for breast cancer therapeutics has driven innovation, leading to new and improved treatments. It has also improved access to these treatments, benefiting more patients. This presents a significant opportunity for the Asia Pacific breast cancer therapeutics market growth as pharmaceutical companies and healthcare providers continue to invest in research and development activities and expand their offerings to meet the growing demand.

On the contrary, high cost of diagnosis and treatment hampers the growth Asia Pacific breast cancer therapeutics market.

Based on drug therapy, the Asia Pacific breast cancer therapeutics market is segmented into targeted drug therapy, hormonal drug therapy, chemotherapy, and immunotherapy/ biological therapy. The targeted drug therapy segment held 63.7% share of the Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 4,450.77 million. It is projected to garner US$ 10,637.22 million by 2030 to expand at 11.5% CAGR during 2022-2030.

In terms of breast cancer type, the Asia Pacific breast cancer therapeutics market is segmented into hormone receptor, HER2+, and triple-negative breast cancer. The hormone receptor segment held 67.4% share of the Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 4,712.10 million. It is projected to garner US$ 11,063.48 million by 2030 to expand at 11.3% CAGR during 2022-2030.

By distribution channel, the Asia Pacific breast cancer therapeutics market is segmented into hospital pharmacies, drug store and retail pharmacies, and online pharmacies. The hospital pharmacies segment held 75.3% share of Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 5,262.43 million. It is projected to garner US$ 12,176.71 million by 2030 to expand at 11.1% CAGR during 2022-2030.

Based on country, the Asia Pacific breast cancer therapeutics market is categorized into Australia, China, India, Japan, South Korea, and the Rest of Asia Pacific. China held 24.9% shares of Asia Pacific breast cancer therapeutics market in 2022, amassing US$ 1,742.42 million. It is projected to garner US$ 4,339.68 million by 2030 to expand at 12.1% CAGR during 2022-2030.

Key players operating in the Asia Pacific breast cancer therapeutics market are Eli Lilly and Co, Eisai Co Ltd, Novartis AG, AstraZeneca Plc, Pfizer Inc, Gilead Sciences Inc, Merck & Co Inc, Teva Pharmaceutical Industries Ltd, and Amgen Inc and Amgen Inc, among others.

- In Jul 2021, Pfizer Inc. and Arvinas, Inc. entered into a global collaboration to develop and commercialize ARV-471, an investigational oral PROTAC (PROteolysis TArgeting Chimera) estrogen receptor protein degrader. The estrogen receptor is a well-known disease driver in most breast cancers. ARV-471 is in a Phase 2 dose expansion clinical trial for treating patients with ER+/HER2- locally advanced or metastatic breast cancer. Under the agreements terms, Pfizer paid Arvinas US$ 650 million upfront. Separately, Pfizer made a US$ 350 million equity investment in Arvinas. The companies will share worldwide development costs, commercialization expenses, and profits equally.

- In Mar 2023, Novartis announced positive topline results from an interim analysis of NATALEE, a Phase III trial evaluating Kisqali (ribociclib) plus endocrine therapy (ET) in a broad population of patients with HR+/HER2- early breast cancer at risk of recurrence. Kisqali plus ET significantly reduced the risk of disease recurrence, compared to standard adjuvant ET alone, with consistent benefit in patients with stage II and stage III early breast cancer regardless of nodal involvement.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com